Clinical Trial News and Research

RSS

Child cancer survival rate progress threatened by lack of new drug development

Remarkable improvements in survival from childhood cancer have taken place in high- income countries over the past 50 years, but further progress is being threatened by increasingly strict research regulations and insufficient development of new drugs, according to a major new Lancet Oncology Series on improving cancer care for children and young people.

20 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Heart OMics in AGEing project receives European Commission grant

The HOMAGE (Heart OMics in AGEing) project, coordinated by the French National Institute of Health and Medical Research (INSERM), has been awarded a grant by the European Commission for a 6 year period.

20 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013

Study reveals rare look into success of substance abuse treatment programs for African-Americans

New research out of the University of Cincinnati reveals a relatively rare look into the success of substance abuse treatment programs for African-Americans. Researchers report that self-motivation could be an important consideration into deciding on the most effective treatment strategy.

20 Feb 2013

SanMedica’s SeroVital-hgh could revolutionize both anti-aging and weight-loss industries

While the Obesity Society's prestigious 30th Annual Scientific Meeting is the venue for some of the most cutting-edge obesity research in the world, at this year's conference the main highlight wasn't weight loss, but was instead — believe it or not — anti-aging. Research presented by a group of highly renowned scientists revealed an oral compound that experts are predicting could completely revolutionize both the anti-aging and weight-loss industries.

20 Feb 2013

Tranylcypromine may also hold promise in treating sickle cell disease

An antidepressant drug used since the 1960s may also hold promise for treating sickle cell disease, according to a surprising new finding made in mice and human red blood cells by a team from the University of Michigan Medical School.

19 Feb 2013

Oncolytics Biotech to commence underwritten public offering of common shares

Oncolytics Biotech Inc. announced today its intention, subject to market and other conditions, to commence an underwritten public offering of common shares. The number of common shares to be distributed and the price of each common share will be determined in the context of the market with final terms to be determined at the time of pricing.

19 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors.

19 Feb 2013

Antimuscarinic effective for overactive bladder in elderly

The antimuscarinic drug fesoterodine seems to be an effective and well-tolerated treatment for elderly individuals with an overactive bladder, including those older than 75 years, show findings from a clinical trial.

19 Feb 2013

Study paves way for new prosthetics that connect directly to the nervous system

For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.

18 Feb 2013

MSU to launch levetiracetam clinical trial for treatment of African children with epilepsy

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

16 Feb 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

15 Feb 2013

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens.

15 Feb 2013

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

15 Feb 2013

Stress and mental illness: an interview with Professor Akira Sawa

As a psychiatrist I am interested in how stress may play a role in the pathology of adult mental disorders. You may know that most of the major mental illnesses, such as schizophrenia, mood-disorder, substance abuse or even anxiety disorder, become prominent in early adulthood.

14 Feb 2013

Probiotics shows promise in reducing both incidence and severity of necrotizing enterocolitis

"Good" bacteria that live in our intestines have been linked with a variety of health benefits, from fighting disease to preventing obesity. In a new study, Kriston Ganguli of Massachusetts General Hospital for Children and Harvard Medical School and her colleagues have discovered another advantage to these friendly microscopic tenants: Chemicals secreted by good bacteria that typically live in the intestines of babies could reduce the frequency and severity of a common and often-lethal disease of premature infants.

14 Feb 2013

IAP antagonists may actually increase risk of bone tumors

Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone, according to researchers at Washington University School of Medicine in St. Louis.

14 Feb 2013

Clinical Trial News and Research

Child cancer survival rate progress threatened by lack of new drug development

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Heart OMics in AGEing project receives European Commission grant

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Study reveals rare look into success of substance abuse treatment programs for African-Americans

SanMedica’s SeroVital-hgh could revolutionize both anti-aging and weight-loss industries

Tranylcypromine may also hold promise in treating sickle cell disease

Oncolytics Biotech to commence underwritten public offering of common shares

BioCryst fourth quarter revenues decrease to $4.1 million

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Antimuscarinic effective for overactive bladder in elderly

Study paves way for new prosthetics that connect directly to the nervous system

MSU to launch levetiracetam clinical trial for treatment of African children with epilepsy

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Stress and mental illness: an interview with Professor Akira Sawa

Probiotics shows promise in reducing both incidence and severity of necrotizing enterocolitis

IAP antagonists may actually increase risk of bone tumors

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer